// App-Quantinova.ai

: Dose-Adjusted Intensive Chemotherapy Is Safe and Tolerable in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Anne S. Renteria

Principal Investigators

  • Sangeetha Venugopal

  • Bridget Marcellino

  • Alla Keyzner

  • Marina Kremyanskaya

  • Vesna Najfeld

  • John Mascarenhas

Medical Centers

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Division of Hematology/Medical Oncology, The Tisch Cancer Institute,Icahn School of Medicine at Mount Sinai,New York,United States;Myeloproliferative Neoplasm Research Consortium (MPN-RC),New York,United States

  • Icahn School of Medicine at Mount Sinai, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • B-lymphocyte antigen CD20

  • Breakpoint Cluster Region

  • Antithrombin III

Drug/Treatment

  • Methotrexate

  • Fibrinogen (IV)

  • Prednisone

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved